The immunological and metabolic landscape in primary and metastatic liver cancer.
Journal
Nature reviews. Cancer
ISSN: 1474-1768
Titre abrégé: Nat Rev Cancer
Pays: England
ID NLM: 101124168
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
accepted:
18
06
2021
pubmed:
31
7
2021
medline:
24
9
2021
entrez:
30
7
2021
Statut:
ppublish
Résumé
The liver is the sixth most common site of primary cancer in humans, and generally arises in a background of cirrhosis and inflammation. Moreover, the liver is frequently colonized by metastases from cancers of other organs (particularly the colon) because of its anatomical location and organization, as well as its unique metabolic and immunosuppressive environment. In this Review, we discuss how the hepatic microenvironment adapts to pathologies characterized by chronic inflammation and metabolic alterations. We illustrate how these immunological or metabolic changes alter immunosurveillance and thus hinder or promote the development of primary liver cancer. In addition, we describe how inflammatory and metabolic niches affect the spreading of cancer metastases into or within the liver. Finally, we review the current therapeutic options in this context and the resulting challenges that must be surmounted.
Identifiants
pubmed: 34326518
doi: 10.1038/s41568-021-00383-9
pii: 10.1038/s41568-021-00383-9
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
541-557Informations de copyright
© 2021. Springer Nature Limited.
Références
Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 7, 6 (2021). This article provides the latest progress in the pathogenic mechanisms of HCC and its therapy.
pubmed: 33479224
doi: 10.1038/s41572-020-00240-3
Ringelhan, M., Pfister, D., O’Connor, T., Pikarsky, E. & Heikenwalder, M. The immunology of hepatocellular carcinoma. Nat. Immunol. 19, 222–232 (2018).
pubmed: 29379119
doi: 10.1038/s41590-018-0044-z
Keenan, B. P., Fong, L. & Kelley, R. K. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J. Immunother. Cancer 7, 1–13 (2019).
doi: 10.1186/s40425-019-0749-z
Kanwal, F. et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology 155, 1828–1837.e2 (2018).
pubmed: 30144434
doi: 10.1053/j.gastro.2018.08.024
Protzer, U., Maini, M. K. & Knolle, P. A. Living in the liver: hepatic infections. Nat. Rev. Immunol. 12, 201–213 (2012).
pubmed: 22362353
doi: 10.1038/nri3169
European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 69, 182–236 (2018).
doi: 10.1016/j.jhep.2018.03.019
Carrat, F. et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 393, 1453–1464 (2019).
pubmed: 30765123
doi: 10.1016/S0140-6736(18)32111-1
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O. & Heikenwalder, M. From NASH to HCC: current concepts and future challenges. Nat. Rev. Gastroenterol. Hepatol. 16, 411–428 (2019).
pubmed: 31028350
doi: 10.1038/s41575-019-0145-7
Steeg, P. S. Tumor metastasis: mechanistic insights and clinical challenges. Nat. Med. 12, 895–904 (2006).
pubmed: 16892035
doi: 10.1038/nm1469
Milette, S., Sicklick, J. K., Lowy, A. M. & Brodt, P. Molecular pathways: targeting the microenvironment of liver metastases. Clin. Cancer Res. 23, 6390–6399 (2017).
pubmed: 28615370
pmcid: 5668192
doi: 10.1158/1078-0432.CCR-15-1636
de Ridder, J. et al. Incidence and origin of histologically confirmed liver metastases: an explorative case-study of 23,154 patients. Oncotarget 7, 55368–55376 (2016).
pubmed: 27421135
pmcid: 5342423
doi: 10.18632/oncotarget.10552
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020).
pubmed: 31912902
doi: 10.3322/caac.21590
Abou-Alfa, G. K. et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379, 54–63 (2018).
pubmed: 29972759
pmcid: 7523244
doi: 10.1056/NEJMoa1717002
Llovet, J. M., Montal, R. & Villanueva, A. Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival. J. Hepatol. 70, 1262–1277 (2019).
pubmed: 30943423
doi: 10.1016/j.jhep.2019.01.028
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
pubmed: 18650514
doi: 10.1056/NEJMoa0708857
Nault, J. C., Cheng, A. L., Sangro, B. & Llovet, J. M. Milestones in the pathogenesis and management of primary liver cancer. J. Hepatol. 72, 209–214 (2020). This paper summarizes important events in the medical history of primary liver cancer and discusses the most current discoveries.
pubmed: 31954486
doi: 10.1016/j.jhep.2019.11.006
Rizvi, S., Khan, S. A., Hallemeier, C. L., Kelley, R. K. & Gores, G. J. Cholangiocarcinoma — evolving concepts and therapeutic strategies. Nat. Rev. Clin. Oncol. 15, 95–111 (2018).
pubmed: 28994423
doi: 10.1038/nrclinonc.2017.157
Vogel, A. et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29, iv238–iv255 (2018).
pubmed: 30285213
doi: 10.1093/annonc/mdy308
Mizukoshi, E. & Kaneko, S. Immune cell therapy for hepatocellular carcinoma. J. Hematol. Oncol. 12, 52 (2019).
pubmed: 31142330
pmcid: 6542133
doi: 10.1186/s13045-019-0742-5
Kudo, M. Combination cancer immunotherapy in hepatocellular carcinoma. Liver Cancer 7, 20–27 (2018).
pubmed: 29662830
pmcid: 5892358
doi: 10.1159/000486487
Heymann, F. et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells. Hepatology 62, 279–291 (2015).
pubmed: 25810240
doi: 10.1002/hep.27793
Jenne, C. N. & Kubes, P. Immune surveillance by the liver. Nat. Immunol. 14, 996–1006 (2013).
pubmed: 24048121
doi: 10.1038/ni.2691
Knolle, P. A. & Thimme, R. Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology 146, 1193–1207 (2014).
pubmed: 24412289
doi: 10.1053/j.gastro.2013.12.036
Winau, F. et al. Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity 26, 117–129 (2007).
pubmed: 17239632
doi: 10.1016/j.immuni.2006.11.011
Thomson, A. W. & Knolle, P. A. Antigen-presenting cell function in the tolerogenic liver environment. Nat. Rev. Immunol. 10, 753–766 (2010).
pubmed: 20972472
doi: 10.1038/nri2858
Thomson, A. W., Vionnet, J. & Sanchez-Fueyo, A. Understanding, predicting and achieving liver transplant tolerance: from bench to bedside. Nat. Rev. Gastroenterol. Hepatol. 17, 719–739 (2020).
pubmed: 32759983
doi: 10.1038/s41575-020-0334-4
Krueger, P. D., Kim, T. S., Sung, S. S., Braciale, T. J. & Hahn, Y. S. Liver-resident CD103
pubmed: 25712214
doi: 10.4049/jimmunol.1402622
Deczkowska, A. et al. XCR1
pubmed: 34017133
doi: 10.1038/s41591-021-01344-3
Peng, H. et al. Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. J. Clin. Invest. 123, 1444–1456 (2013).
pubmed: 23524967
pmcid: 3613925
doi: 10.1172/JCI66381
Paust, S. et al. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat. Immunol. 11, 1127–1135 (2010).
pubmed: 20972432
pmcid: 2982944
doi: 10.1038/ni.1953
Lassen, M. G., Lukens, J. R., Dolina, J. S., Brown, M. G. & Hahn, Y. S. Intrahepatic IL-10 maintains NKG2A
pubmed: 20124099
doi: 10.4049/jimmunol.0901362
Hoechst, B. et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50, 799–807 (2009).
pubmed: 19551844
doi: 10.1002/hep.23054
Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162–174 (2009).
pubmed: 19197294
pmcid: 2828349
doi: 10.1038/nri2506
Curiel, T. J. Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117, 1167–1174 (2007).
pubmed: 17476346
pmcid: 1857250
doi: 10.1172/JCI31202
Diehl, L. et al. Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8
pubmed: 17975811
doi: 10.1002/hep.21965
Limmer, A. et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8
pubmed: 11100119
doi: 10.1038/82161
Aizarani, N. et al. A human liver cell atlas reveals heterogeneity and epithelial progenitors. Nature 572, 199–204 (2019).
pubmed: 31292543
pmcid: 6687507
doi: 10.1038/s41586-019-1373-2
Peng, W. C. et al. Inflammatory cytokine TNFα promotes the long-term expansion of primary hepatocytes in 3D culture. Cell 175, 1607–1619.e15 (2018).
pubmed: 30500539
pmcid: 6497386
doi: 10.1016/j.cell.2018.11.012
Berndt, N. et al. Functional consequences of metabolic zonation in murine livers: insights for an old story. Hepatology 73, 795–810 (2021).
pubmed: 32286709
doi: 10.1002/hep.31274
Halpern, K. B. et al. Single-cell spatial reconstruction reveals global division of labour in the mammalian liver. Nature 542, 352–356 (2017).
pubmed: 28166538
pmcid: 5321580
doi: 10.1038/nature21065
Droin, C. et al. Space–time logic of liver gene expression at sub-lobular scale. Nat. Metab. 3, 43–58 (2021). This article reveals how liver function is compartmentalized spatiotemporally at the sub-lobular scale.
pubmed: 33432202
pmcid: 7116850
doi: 10.1038/s42255-020-00323-1
Planas-Paz, L. et al. The RSPO–LGR4/5–ZNRF3/RNF43 module controls liver zonation and size. Nat. Cell Biol. 18, 467–479 (2016).
pubmed: 27088858
doi: 10.1038/ncb3337
Inverso, D. et al. A spatial vascular transcriptomic, proteomic, and phosphoproteomic atlas unveils an angiocrine Tie–Wnt signaling axis in the liver. Dev. Cell 56, 1677–1693.e10 (2021).
pubmed: 34038707
pmcid: 8191494
doi: 10.1016/j.devcel.2021.05.001
Keegan, A., Martini, R. & Batey, R. Ethanol-related liver injury in the rat: a model of steatosis, inflammation and pericentral fibrosis. J. Hepatol. 23, 591–600 (1995).
pubmed: 8583149
doi: 10.1016/0168-8278(95)80067-0
Hall, Z. et al. Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease. Hepatology 65, 1165–1180 (2017).
pubmed: 27863448
doi: 10.1002/hep.28953
Michelotti, G. A., Machado, M. V. & Diehl, A. M. NAFLD, NASH and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 10, 656–665 (2013).
pubmed: 24080776
doi: 10.1038/nrgastro.2013.183
Lackner, C. Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist’s perspective. Expert Rev. Gastroenterol. Hepatol. 5, 223–231 (2011).
pubmed: 21476917
doi: 10.1586/egh.11.8
Malehmir, M. et al. Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer. Nat. Med. 25, 641–655 (2019). This paper provides a rationale for antiplatelet therapy in reverting NASH and preventing NASH-to-HCC transition.
pubmed: 30936549
doi: 10.1038/s41591-019-0379-5
Wolf, M. J. et al. Metabolic activation of intrahepatic CD8
doi: 10.1016/j.ccell.2014.09.003
pubmed: 25314080
Kietzmann, T. Liver zonation in health and disease: hypoxia and hypoxia-inducible transcription factors as concert masters. Int. J. Mol. Sci. 20, 2347 (2019).
pmcid: 6540308
doi: 10.3390/ijms20092347
Kudo, Y. et al. PKCλ/ι loss induces autophagy, oxidative phosphorylation, and NRF2 to promote liver cancer progression. Cancer Cell 38, 247–262.e11 (2020).
pubmed: 32589943
pmcid: 7423690
doi: 10.1016/j.ccell.2020.05.018
Wilson, G. K., Tennant, D. A. & McKeating, J. A. Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions. J. Hepatol. 61, 1397–1406 (2014).
pubmed: 25157983
doi: 10.1016/j.jhep.2014.08.025
Wing, P. A. C. et al. Hypoxia inducible factors regulate hepatitis B virus replication by activating the basal core promoter. J. Hepatol. 75, 64–73 (2021).
pubmed: 33516779
pmcid: 8214165
doi: 10.1016/j.jhep.2020.12.034
Moreau, M. et al. Hepatitis C viral proteins perturb metabolic liver zonation. J. Hepatol. 62, 278–285 (2015).
pubmed: 25220251
doi: 10.1016/j.jhep.2014.09.004
Gautheron, J. et al. A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol. Med. 6, 1062–1074 (2014).
pubmed: 24963148
pmcid: 4154133
doi: 10.15252/emmm.201403856
Boege, Y. et al. A dual role of caspase-8 in triggering and sensing proliferation-associated DNA damage, a key determinant of liver cancer development. Cancer Cell 32, 342–359.e10 (2017). This article illustrates diverging mechanistic links of caspase 8 to cancer biology in the liver.
pubmed: 28898696
pmcid: 5598544
doi: 10.1016/j.ccell.2017.08.010
Holze, C. et al. Oxeiptosis, a ROS-induced caspase-independent apoptosis-like cell-death pathway. Nat. Immunol. 19, 130–140 (2018).
pubmed: 29255269
doi: 10.1038/s41590-017-0013-y
Seehawer, M. et al. Necroptosis microenvironment directs lineage commitment in liver cancer. Nature 562, 69–75 (2018). This article sheds light on lineage commitment during liver carcinogenesis and elucidates the molecular basis for common liver-damaging risk factors that result in either HCC or CCA.
pubmed: 30209397
pmcid: 8111790
doi: 10.1038/s41586-018-0519-y
Faubion, W. A. et al. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J. Clin. Invest. 103, 137–145 (1999).
pubmed: 9884343
pmcid: 407865
doi: 10.1172/JCI4765
Brenner, C., Galluzzi, L., Kepp, O. & Kroemer, G. Decoding cell death signals in liver inflammation. J. Hepatol. 59, 583–594 (2013).
pubmed: 23567086
doi: 10.1016/j.jhep.2013.03.033
Asselah, T. et al. In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C. J. Pathol. 221, 264–274 (2010).
pubmed: 20527020
doi: 10.1002/path.2703
Merquiol, E. et al. HCV causes chronic endoplasmic reticulum stress leading to adaptation and interference with the unfolded protein response. PLoS ONE 6, e24660 (2011).
pubmed: 21949742
pmcid: 3176279
doi: 10.1371/journal.pone.0024660
Roos, W. P., Thomas, A. D. & Kaina, B. DNA damage and the balance between survival and death in cancer biology. Nat. Rev. Cancer 16, 20–33 (2016).
pubmed: 26678314
doi: 10.1038/nrc.2015.2
Brumatti, G., Salmanidis, M. & Ekert, P. G. Crossing paths: interactions between the cell death machinery and growth factor survival signals. Cell Mol. Life Sci. 67, 1619–1630 (2010).
pubmed: 20157838
doi: 10.1007/s00018-010-0288-8
Farazi, P. A. & DePinho, R. A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6, 674–687 (2006).
pubmed: 16929323
doi: 10.1038/nrc1934
Roychowdhury, S., McMullen, M. R., Pisano, S. G., Liu, X. & Nagy, L. E. Absence of receptor interacting protein kinase 3 prevents ethanol-induced liver injury. Hepatology 57, 1773–1783 (2013).
pubmed: 23319235
doi: 10.1002/hep.26200
Linkermann, A., Stockwell, B. R., Krautwald, S. & Anders, H. J. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat. Rev. Immunol. 14, 759–767 (2014).
pubmed: 25324125
doi: 10.1038/nri3743
Newton, K. et al. Cleavage of RIPK1 by caspase-8 is crucial for limiting apoptosis and necroptosis. Nature 574, 428–431 (2019).
pubmed: 31511692
doi: 10.1038/s41586-019-1548-x
Upton, J. W., Kaiser, W. J. & Mocarski, E. S. DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe 11, 290–297 (2012).
pubmed: 22423968
pmcid: 3531981
doi: 10.1016/j.chom.2012.01.016
Li, J. et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell 150, 339–350 (2012).
pubmed: 22817896
pmcid: 3664196
doi: 10.1016/j.cell.2012.06.019
Murphy, J. M. et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 39, 443–453 (2013).
pubmed: 24012422
doi: 10.1016/j.immuni.2013.06.018
Malhi, H., Gores, G. J. & Lemasters, J. J. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology 43, S31–S44 (2006).
pubmed: 16447272
doi: 10.1002/hep.21062
Caesar, R. et al. Gut-derived lipopolysaccharide augments adipose macrophage accumulation but is not essential for impaired glucose or insulin tolerance in mice. Gut 61, 1701–1707 (2012).
pubmed: 22535377
doi: 10.1136/gutjnl-2011-301689
Sutti, S. et al. Adaptive immune responses triggered by oxidative stress contribute to hepatic inflammation in NASH. Hepatology 59, 886–897 (2014).
pubmed: 24115128
doi: 10.1002/hep.26749
Sutti, S. & Albano, E. Adaptive immunity: an emerging player in the progression of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 17, 81–92 (2020).
pubmed: 31605031
doi: 10.1038/s41575-019-0210-2
Wang, H. et al. TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection. J. Hepatol. 72, 45–56 (2020).
pubmed: 31499130
doi: 10.1016/j.jhep.2019.08.024
Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, cancer. Cell 140, 883–899 (2010).
pubmed: 20303878
pmcid: 2866629
doi: 10.1016/j.cell.2010.01.025
Kopp, J. L., Grompe, M. & Sander, M. Stem cells versus plasticity in liver and pancreas regeneration. Nat. Cell Biol. 18, 238–245 (2016).
pubmed: 26911907
doi: 10.1038/ncb3309
Yanger, K. et al. Robust cellular reprogramming occurs spontaneously during liver regeneration. Genes Dev. 27, 719–724 (2013).
pubmed: 23520387
pmcid: 3639413
doi: 10.1101/gad.207803.112
Sakurai, T. et al. Hepatocyte necrosis induced by oxidative stress and IL-1α release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 14, 156–165 (2008).
pubmed: 18691550
pmcid: 2707922
doi: 10.1016/j.ccr.2008.06.016
Flecken, T. et al. Immunodominance and functional alterations of tumor-associated antigen-specific CD8
pubmed: 24002931
doi: 10.1002/hep.26731
Macdonald, R. Lifespan of liver cells — autoradiographic study using tritiated thymidine in normal, cirrhotic, and partially hepatectomized rats. Arch. Intern. Med. 107, 335–343 (1961).
pubmed: 13764742
doi: 10.1001/archinte.1961.03620030023003
Karin, M. & Clevers, H. Reparative inflammation takes charge of tissue regeneration. Nature 529, 307–315 (2016).
pubmed: 26791721
pmcid: 5228603
doi: 10.1038/nature17039
Yuan, D. T. et al. Kupffer cell-derived Tnf triggers cholangiocellular tumorigenesis through JNK due to chronic mitochondrial dysfunction and ROS. Cancer Cell 31, 771–789 (2017).
pubmed: 28609656
pmcid: 7909318
doi: 10.1016/j.ccell.2017.05.006
Pikarsky, E. et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461–466 (2004).
pubmed: 15329734
doi: 10.1038/nature02924
Park, E. J. et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197–208 (2010).
pubmed: 20141834
pmcid: 2836922
doi: 10.1016/j.cell.2009.12.052
Finkin, S. et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat. Immunol. 16, 1235–1244 (2015).
pubmed: 26502405
pmcid: 4653079
doi: 10.1038/ni.3290
Takai, A. et al. A novel mouse model of hepatocarcinogenesis triggered by AID causing deleterious p53 mutations. Oncogene 28, 469–478 (2009).
pubmed: 18997814
doi: 10.1038/onc.2008.415
Marrogi, A. J. et al. Oxidative stress and p53 mutations in the carcinogenesis of iron overload-associated hepatocellular carcinoma. J. Natl Cancer Inst. 93, 1652–1655 (2001).
pubmed: 11698570
doi: 10.1093/jnci/93.21.1652
Elinav, E. et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer 13, 759–771 (2013).
pubmed: 24154716
doi: 10.1038/nrc3611
Stauffer, J. K., Scarzello, A. J., Jiang, Q. & Wiltrout, R. H. Chronic inflammation, immune escape, and oncogenesis in the liver: a unique neighborhood for novel intersections. Hepatology 56, 1567–1574 (2012).
pubmed: 22378061
doi: 10.1002/hep.25674
Grohmann, M. et al. Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC. Cell 175, 1289–1306.e20 (2018). This article demonstrates that obesity-related hepatic oxidative stress might contribute independently to the aetiology of NASH, fibrosis and HCC.
pubmed: 30454647
pmcid: 6242467
doi: 10.1016/j.cell.2018.09.053
Xue, R. et al. Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. Cancer Cell 35, 932–947.e8 (2019). This paper demonstrates that combined and mixed forms of HCC–CCA exhibit distinct clinical and molecular characteristics and identifies Nestin as a potential marker for diagnosis of HCC–CCA.
pubmed: 31130341
pmcid: 8317046
doi: 10.1016/j.ccell.2019.04.007
Mu, X. et al. Hepatocellular carcinoma originates from hepatocytes and not from the progenitor/biliary compartment. J. Clin. Invest. 125, 3891–3903 (2015).
pubmed: 26348897
pmcid: 4607132
doi: 10.1172/JCI77995
Sia, D., Villanueva, A., Friedman, S. L. & Llovet, J. M. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology 152, 745–761 (2017).
pubmed: 28043904
doi: 10.1053/j.gastro.2016.11.048
Ko, S., Russell, J. O., Molina, L. M. & Monga, S. P. Liver progenitors and adult cell plasticity in hepatic injury and repair: knowns and unknowns. Annu. Rev. Pathol. 15, 23–50 (2020).
pubmed: 31399003
doi: 10.1146/annurev-pathmechdis-012419-032824
Marquardt, J. U., Andersen, J. B. & Thorgeirsson, S. S. Functional and genetic deconstruction of the cellular origin in liver cancer. Nat. Rev. Cancer 15, 653–667 (2015).
pubmed: 26493646
doi: 10.1038/nrc4017
Okabe, H. et al. Wnt signaling regulates hepatobiliary repair following cholestatic liver injury in mice. Hepatology 64, 1652–1666 (2016).
pubmed: 27533619
doi: 10.1002/hep.28774
Hyun, J. et al. Dysregulated activation of fetal liver programme in acute liver failure. Gut 68, 1076–1087 (2019).
pubmed: 30670575
doi: 10.1136/gutjnl-2018-317603
Komuta, M. et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology 55, 1876–1888 (2012).
pubmed: 22271564
doi: 10.1002/hep.25595
Banales, J. M. et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat. Rev. Gastroenterol. Hepatol. 13, 261–280 (2016).
pubmed: 27095655
doi: 10.1038/nrgastro.2016.51
Komuta, M. et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 47, 1544–1556 (2008).
pubmed: 18393293
doi: 10.1002/hep.22238
Brunt, E. et al. cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology 68, 113–126 (2018).
pubmed: 29360137
doi: 10.1002/hep.29789
Satriano, L., Lewinska, M., Rodrigues, P. M., Banales, J. M. & Andersen, J. B. Metabolic rearrangements in primary liver cancers: cause and consequences. Nat. Rev. Gastroenterol. Hepatol. 16, 748–766 (2019). This review discusses the impact of metabolic liver disturbances and the effects on primary liver cancer.
pubmed: 31666728
doi: 10.1038/s41575-019-0217-8
Yamashita, T. et al. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J. Hepatol. 50, 100–110 (2009).
pubmed: 19008011
doi: 10.1016/j.jhep.2008.07.036
Wang, M. et al. Dysregulated fatty acid metabolism in hepatocellular carcinoma. Hepat. Oncol. 3, 241–251 (2016).
pubmed: 30191046
doi: 10.2217/hep-2016-0012
Xia, S., Pan, Y., Liang, Y., Xu, J. & Cai, X. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine 51, 102610 (2020).
pubmed: 31918403
pmcid: 7000339
doi: 10.1016/j.ebiom.2019.102610
Ma, M. K. F. et al. Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation. J. Hepatol. 67, 979–990 (2017).
pubmed: 28647567
doi: 10.1016/j.jhep.2017.06.015
Rudalska, R. et al. LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. Nat. Cancer 2, 201–217 (2021).
doi: 10.1038/s43018-020-00168-3
pubmed: 35122079
Lally, J. S. V. et al. Inhibition of acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma. Cell Metab. 29, 174–182.e5 (2019).
pubmed: 30244972
doi: 10.1016/j.cmet.2018.08.020
Saha, S. K. et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature 513, 110–114 (2014). This article establishes a functional relationship between IDH mutations and CCA pathogenesis, and provides a novel genetically engineered mouse model of IDH-driven malignancy.
pubmed: 25043045
pmcid: 4499230
doi: 10.1038/nature13441
Saha, S. K. et al. Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma. Cancer Discov. 6, 727–739 (2016).
pubmed: 27231123
pmcid: 5458737
doi: 10.1158/2159-8290.CD-15-1442
Wu, E. M. et al. Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. Hepatoma Res. 4, 66 (2018).
pubmed: 30687780
pmcid: 6347119
doi: 10.20517/2394-5079.2018.87
Manieri, E. et al. Adiponectin accounts for gender differences in hepatocellular carcinoma incidence. J. Exp. Med. 216, 1108–1119 (2019).
pubmed: 30944152
pmcid: 6504215
doi: 10.1084/jem.20181288
Ma, C. et al. NAFLD causes selective CD4
pubmed: 26934227
pmcid: 4786464
doi: 10.1038/nature16969
Zhang, Q. et al. Fatty acid oxidation contributes to IL-1β secretion in M2 macrophages and promotes macrophage-mediated tumor cell migration. Mol. Immunol. 94, 27–35 (2018).
pubmed: 29248877
doi: 10.1016/j.molimm.2017.12.011
Pacella, I. et al. Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth. Proc. Natl Acad. Sci. USA 115, E6546–E6555 (2018).
pubmed: 29941600
pmcid: 6048537
doi: 10.1073/pnas.1720113115
Li, T.-E. et al. PKM2 drives hepatocellular carcinoma progression by inducing immunosuppressive microenvironment. Front. Immunol. 11, 2722 (2020).
doi: 10.3389/fimmu.2020.589997
Chen, D. P. et al. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3–PD-L1 axis in human hepatocellular carcinoma. J. Hepatol. 71, 333–343 (2019).
pubmed: 31071366
doi: 10.1016/j.jhep.2019.04.007
Klein, G. Cancer, apoptosis, and nonimmune surveillance. Cell Death Differ. 11, 13–17 (2004).
pubmed: 14615800
doi: 10.1038/sj.cdd.4401342
Dhar, D. et al. Liver cancer initiation requires p53 inhibition by CD44-enhanced growth factor signaling. Cancer Cell 33, 1061–1077.e6 (2018).
pubmed: 29894692
pmcid: 6005359
doi: 10.1016/j.ccell.2018.05.003
Tschaharganeh, D. F. et al. p53-Dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell 158, 579–592 (2014).
pubmed: 25083869
pmcid: 4221237
doi: 10.1016/j.cell.2014.05.051
Kang, T. W. et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479, 547–551 (2011).
pubmed: 22080947
doi: 10.1038/nature10599
Mizukoshi, E. et al. Comparative analysis of various tumor-associated antigen-specific T-cell responses in patients with hepatocellular carcinoma. Hepatology 53, 1206–1216 (2011).
pubmed: 21480325
doi: 10.1002/hep.24149
Endig, J. et al. Dual role of the adaptive immune system in liver injury and hepatocellular carcinoma development. Cancer Cell 30, 308–323 (2016).
pubmed: 27478039
doi: 10.1016/j.ccell.2016.06.009
Fu, J. et al. Impairment of CD4
pubmed: 22961630
doi: 10.1002/hep.26054
Garnelo, M. et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut 66, 342–351 (2017).
pubmed: 26669617
doi: 10.1136/gutjnl-2015-310814
Chen, K. J. et al. Selective recruitment of regulatory T cell through CCR6–CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS ONE 6, e24671 (2011).
pubmed: 21935436
pmcid: 3173477
doi: 10.1371/journal.pone.0024671
Fu, J. et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132, 2328–2339 (2007).
pubmed: 17570208
doi: 10.1053/j.gastro.2007.03.102
Gallimore, A. M. & Simon, A. K. Positive and negative influences of regulatory T cells on tumour immunity. Oncogene 27, 5886–5893 (2008).
pubmed: 18836469
doi: 10.1038/onc.2008.269
Ghiringhelli, F., Menard, C., Martin, F. & Zitvogel, L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol. Rev. 214, 229–238 (2006).
pubmed: 17100888
doi: 10.1111/j.1600-065X.2006.00445.x
Sun, Y. et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell 184, 404–421.e16 (2021). This paper uses single-cell analysis of primary and recurrent HCC tumours to produce deep insights into immune evasion mechanisms.
pubmed: 33357445
doi: 10.1016/j.cell.2020.11.041
Dudek, M. et al. Auto-aggressive CXCR6
pubmed: 33762736
doi: 10.1038/s41586-021-03233-8
Heinrich, B. et al. Steatohepatitis impairs T-cell-directed immunotherapies against liver tumors in mice. Gastroenterology 160, 331–345.e6 (2021).
pubmed: 33010248
doi: 10.1053/j.gastro.2020.09.031
Pfister, D. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592, 450–456 (2021). This paper supports stratifying patients with HCC according to their underlying aetiology, before using immunotherapy as a main or adjuvant treatment.
pubmed: 33762733
pmcid: 8046670
doi: 10.1038/s41586-021-03362-0
Albertsson, P. A. et al. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol. 24, 603–609 (2003).
pubmed: 14596885
doi: 10.1016/j.it.2003.09.007
Bricard, G. et al. Enrichment of human CD4
pubmed: 19342695
doi: 10.4049/jimmunol.0711086
Crowe, N. Y. et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 202, 1279–1288 (2005).
pubmed: 16275765
pmcid: 1459911
doi: 10.1084/jem.20050953
Pommier, A. et al. Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4
pubmed: 23878221
pmcid: 3740849
doi: 10.1073/pnas.1300314110
Lee, J. W. et al. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature 567, 249–252 (2019).
pubmed: 30842658
pmcid: 6430113
doi: 10.1038/s41586-019-1004-y
Condeelis, J. & Pollard, J. W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124, 263–266 (2006).
pubmed: 16439202
doi: 10.1016/j.cell.2006.01.007
Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49–61 (2014).
pubmed: 25035953
pmcid: 4137410
doi: 10.1016/j.immuni.2014.06.010
Ramachandran, P. et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level. Nature 575, 512–518 (2019).
pubmed: 31597160
pmcid: 6876711
doi: 10.1038/s41586-019-1631-3
Budhu, A. et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10, 99–111 (2006).
pubmed: 16904609
doi: 10.1016/j.ccr.2006.06.016
Zhu, X. D. et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J. Clin. Oncol. 26, 2707–2716 (2008).
pubmed: 18509183
doi: 10.1200/JCO.2007.15.6521
Ciner, A. T., Jones, K., Muschel, R. J. & Brodt, P. The unique immune microenvironment of liver metastases: challenges and opportunities. Semin. Cancer Biol. 71, 143–156 (2021).
pubmed: 32526354
doi: 10.1016/j.semcancer.2020.06.003
Yu, J. et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat. Med. 27, 152–164 (2021). This paper shows that hepatic metastases utilize host peripheral tolerance mechanisms to promote CD8
pubmed: 33398162
pmcid: 8095049
doi: 10.1038/s41591-020-1131-x
Fidler, I. J. Timeline — the pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat. Rev. Cancer 3, 453–458 (2003).
pubmed: 12778135
doi: 10.1038/nrc1098
Lorentzen, A. et al. Single cell polarity in liquid phase facilitates tumour metastasis. Nat. Commun. 9, 887 (2018).
pubmed: 29491397
pmcid: 5830403
doi: 10.1038/s41467-018-03139-6
Clark, A. M., Ma, B., Taylor, D. L., Griffith, L. & Wells, A. Liver metastases: microenvironments and ex-vivo models. Exp. Biol. Med. 241, 1639–1652 (2016).
doi: 10.1177/1535370216658144
Benedicto, A., Romayor, I. & Arteta, B. Role of liver ICAM-1 in metastasis. Oncol. Lett. 14, 3883–3892 (2017).
pubmed: 28943897
pmcid: 5604125
doi: 10.3892/ol.2017.6700
Khatib, A. M. et al. Rapid induction of cytokine and E-selectin expression in the liver in response to metastatic tumor cells. Cancer Res. 59, 1356–1361 (1999).
pubmed: 10096570
Brodt, P. Role of the microenvironment in liver metastasis: from pre- to prometastatic niches. Clin. Cancer Res. 22, 5971–5982 (2016).
pubmed: 27797969
doi: 10.1158/1078-0432.CCR-16-0460
Wohlfeil, S. A. et al. Hepatic endothelial notch activation protects against liver metastasis by regulating endothelial-tumor cell adhesion independent of angiocrine signaling. Cancer Res. 79, 598–610 (2019).
pubmed: 30530502
doi: 10.1158/0008-5472.CAN-18-1752
Mendoza, L. et al. Hydrogen peroxide mediates vascular cell adhesion molecule-1 expression from interleukin-18-activated hepatic sinusoidal endothelium: implications for circulating cancer cell arrest in the murine liver. Hepatology 34, 298–310 (2001).
pubmed: 11481615
doi: 10.1053/jhep.2001.26629
Hu, C. T. et al. MIF, secreted by human hepatic sinusoidal endothelial cells, promotes chemotaxis and outgrowth of colorectal cancer in liver prometastasis. Oncotarget 6, 22410–22423 (2015).
pubmed: 26087187
pmcid: 4673172
doi: 10.18632/oncotarget.4198
Ou, J. et al. Endothelial cell-derived fibronectin extra domain A promotes colorectal cancer metastasis via inducing epithelial–mesenchymal transition. Carcinogenesis 35, 1661–1670 (2014).
pubmed: 24743511
doi: 10.1093/carcin/bgu090
Huang, J., Pan, C., Hu, H., Zheng, S. & Ding, L. Osteopontin-enhanced hepatic metastasis of colorectal cancer cells. PLoS ONE 7, e47901 (2012).
pubmed: 23112867
pmcid: 3480452
doi: 10.1371/journal.pone.0047901
Tabaries, S. et al. Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes. Mol. Cell Biol. 32, 2979–2991 (2012).
pubmed: 22645303
pmcid: 3434516
doi: 10.1128/MCB.00299-12
Shimizu, S. et al. Ultrastructure of early phase hepatic metastasis of human colon carcinoma cells with special reference to desmosomal junctions with hepatocytes. Pathol. Int. 50, 953–959 (2000).
pubmed: 11123761
doi: 10.1046/j.1440-1827.2000.01153.x
Yoshioka, T. et al. Significance of integrin αvβ5 and erbB3 in enhanced cell migration and liver metastasis of colon carcinomas stimulated by hepatocyte-derived heregulin. Cancer Sci. 101, 2011–2018 (2010).
pubmed: 20626753
doi: 10.1111/j.1349-7006.2010.01640.x
Bu, P. et al. Aldolase B-mediated fructose metabolism drives metabolic reprogramming of colon cancer liver metastasis. Cell Metab. 27, 1249–1262.e4 (2018).
pubmed: 29706565
pmcid: 5990465
doi: 10.1016/j.cmet.2018.04.003
Li, Y. et al. Hepatic lipids promote liver metastasis. JCI Insight 5, e136215 (2020).
pmcid: 7487169
doi: 10.1172/jci.insight.136215
Wen, S. W., Ager, E. I. & Christophi, C. Bimodal role of Kupffer cells during colorectal cancer liver metastasis. Cancer Biol. Ther. 14, 606–613 (2013).
pubmed: 23792646
pmcid: 3742490
doi: 10.4161/cbt.24593
Costa-Silva, B. et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell Biol. 17, 816–826 (2015).
pubmed: 25985394
pmcid: 5769922
doi: 10.1038/ncb3169
Hoshino, A. et al. Tumour exosome integrins determine organotropic metastasis. Nature 527, 329–335 (2015).
pubmed: 26524530
pmcid: 4788391
doi: 10.1038/nature15756
Shao, Y. et al. Colorectal cancer-derived small extracellular vesicles establish an inflammatory premetastatic niche in liver metastasis. Carcinogenesis 39, 1368–1379 (2018).
pubmed: 30184100
doi: 10.1093/carcin/bgy115
Bhattacharjee, S. et al. Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. J. Clin. Invest. 131, e146987 (2021).
doi: 10.1172/JCI146987
pmcid: 8159701
Iredale, J. P., Thompson, A. & Henderson, N. C. Extracellular matrix degradation in liver fibrosis: biochemistry and regulation. Biochim. Biophys. Acta 1832, 876–883 (2013).
pubmed: 23149387
doi: 10.1016/j.bbadis.2012.11.002
Friedman, S. L. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N. Engl. J. Med. 328, 1828–1835 (1993).
pubmed: 8502273
doi: 10.1056/NEJM199306243282508
Eveno, C. et al. Proof of prometastatic niche induction by hepatic stellate cells. J. Surg. Res. 194, 496–504 (2015).
pubmed: 25528682
doi: 10.1016/j.jss.2014.11.005
Cox, D., Brennan, M. & Moran, N. Integrins as therapeutic targets: lessons and opportunities. Nat. Rev. Drug Discov. 9, 804–820 (2010).
pubmed: 20885411
doi: 10.1038/nrd3266
Zhang, D. Y. & Friedman, S. L. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 56, 769–775 (2012).
pubmed: 22378017
doi: 10.1002/hep.25670
Shen, Y. et al. Reduction of liver metastasis stiffness improves response to bevacizumab in metastatic colorectal cancer. Cancer Cell 37, 800–817.e7 (2020).
pubmed: 32516590
doi: 10.1016/j.ccell.2020.05.005
Zhao, W. et al. Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model. Lab. Invest. 94, 182–191 (2014).
pubmed: 24296878
doi: 10.1038/labinvest.2013.139
Hsu, B. E. et al. Immature low-density neutrophils exhibit metabolic flexibility that facilitates breast cancer liver metastasis. Cell Rep. 27, 3902–3915.e6 (2019).
pubmed: 31242422
doi: 10.1016/j.celrep.2019.05.091
Gordon-Weeks, A. N. et al. Neutrophils promote hepatic metastasis growth through fibroblast growth factor 2-dependent angiogenesis in mice. Hepatology 65, 1920–1935 (2017).
pubmed: 28133764
doi: 10.1002/hep.29088
Haemmerle, M., Stone, R. L., Menter, D. G., Afshar-Kharghan, V. & Sood, A. K. The platelet lifeline to cancer: challenges and opportunities. Cancer Cell 33, 965–983 (2018).
pubmed: 29657130
pmcid: 5997503
doi: 10.1016/j.ccell.2018.03.002
Verheul, H. M. et al. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin. Cancer Res. 13, 4201–4208 (2007).
pubmed: 17634549
doi: 10.1158/1078-0432.CCR-06-2553
Gervaz, P. et al. Angiogenesis of liver metastases: role of sinusoidal endothelial cells. Dis. Colon Rectum 43, 980–986 (2000).
pubmed: 10910247
doi: 10.1007/BF02237364
Kimura, Y. et al. The innate immune receptor Dectin-2 mediates the phagocytosis of cancer cells by Kupffer cells for the suppression of liver metastasis. Proc. Natl Acad. Sci. USA 113, 14097–14102 (2016).
pubmed: 27872290
pmcid: 5150405
doi: 10.1073/pnas.1617903113
Timmers, M. et al. Interactions between rat colon carcinoma cells and Kupffer cells during the onset of hepatic metastasis. Int. J. Cancer 112, 793–802 (2004).
pubmed: 15386374
doi: 10.1002/ijc.20481
Molgora, M. et al. IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity. Nature 551, 110–114 (2017).
pubmed: 29072292
pmcid: 5768243
doi: 10.1038/nature24293
Takeda, K. et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med. 7, 94–100 (2001).
pubmed: 11135622
doi: 10.1038/83416
Ballas, Z. K., Buchta, C. M., Rosean, T. R., Heusel, J. W. & Shey, M. R. Role of NK cell subsets in organ-specific murine melanoma metastasis. PLoS ONE 8, e65599 (2013).
pubmed: 23776508
pmcid: 3679158
doi: 10.1371/journal.pone.0065599
Ducimetière, L. et al. Conventional NK cells and tissue-resident ILC1s join forces to control liver metastasis. Proc. Natl Acad. Sci. USA 118, e2026271118 (2021).
pubmed: 34183415
doi: 10.1073/pnas.2026271118
pmcid: 8271692
Tauriello, D. V. F. et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554, 538–543 (2018).
pubmed: 29443964
doi: 10.1038/nature25492
Lee, J. H. et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 148, 1383–1391.e6 (2015).
pubmed: 25747273
doi: 10.1053/j.gastro.2015.02.055
Lee, J.-H., Oh, S.-Y., Kim, J. Y. & Nishida, N. Cancer immunotherapy for hepatocellular carcinoma. Hepatoma Res. 4, 51 (2018).
doi: 10.20517/2394-5079.2018.78
Zhang, Z. et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature 579, 415–420 (2020).
pubmed: 32188940
pmcid: 7123794
doi: 10.1038/s41586-020-2071-9
Crowther, M. D. et al. Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. Nat. Immunol. 21, 178–185 (2020).
pubmed: 31959982
pmcid: 6983325
doi: 10.1038/s41590-019-0578-8
Sangro, B. et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J. Hepatol. 59, 81–88 (2013).
pubmed: 23466307
doi: 10.1016/j.jhep.2013.02.022
Duffy, A. G. et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J. Hepatol. 66, 545–551 (2017).
pubmed: 27816492
doi: 10.1016/j.jhep.2016.10.029
Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894–1905 (2020). This article reports an improvement of overall survival and progression-free survival in patients with advanced unresectable HCC who were treated with atezolizumab and bevacizumab when compared with sorafenib.
pubmed: 32402160
doi: 10.1056/NEJMoa1915745
Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Primers 2, 16018 (2016).
pubmed: 27158749
doi: 10.1038/nrdp.2016.18
El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389, 2492–2502 (2017).
pubmed: 28434648
pmcid: 7539326
doi: 10.1016/S0140-6736(17)31046-2
Yarchoan, M. et al. Recent developments and therapeutic strategies against hepatocellular carcinoma. Cancer Res. 79, 4326–4330 (2019).
pubmed: 31481419
pmcid: 8330805
doi: 10.1158/0008-5472.CAN-19-0803
Harding, J. J. et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin. Cancer Res. 25, 2116–2126 (2019).
pubmed: 30373752
doi: 10.1158/1078-0432.CCR-18-2293
Jin, H. et al. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. eLife 9, e56749 (2020).
pubmed: 33016874
pmcid: 7535927
doi: 10.7554/eLife.56749
Rizvi, S. & Gores, G. J. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145, 1215–1229 (2013).
pubmed: 24140396
doi: 10.1053/j.gastro.2013.10.013
Rothwell, P. M. et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 392, 387–399 (2018).
pubmed: 30017552
pmcid: 6083400
doi: 10.1016/S0140-6736(18)31133-4
Simon, T. G. et al. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N. Engl. J. Med. 382, 1018–1028 (2020).
pubmed: 32160663
pmcid: 7317648
doi: 10.1056/NEJMoa1912035
Xiong, X. et al. Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis. Mol. Cell 75, 644–660.e5 (2019). This article reports unprecedented insights into intercellular interaction and reprogramming of liver cells in health and disease.
pubmed: 31398325
pmcid: 7262680
doi: 10.1016/j.molcel.2019.07.028
Gola, A. et al. Commensal-driven immune zonation of the liver promotes host defence. Nature 589, 131–136 (2021). This paper explains the link between the localization of hepatic immune cells and host protection.
pubmed: 33239787
doi: 10.1038/s41586-020-2977-2
Manco, R. & Itzkovitz, S. Liver zonation. J. Hepatol. 74, 466–468 (2021).
pubmed: 33317845
doi: 10.1016/j.jhep.2020.09.003
Krenkel, O. et al. Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis. Gut 69, 551–563 (2020).
pubmed: 31076404
doi: 10.1136/gutjnl-2019-318382
MacParland, S. A. et al. Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. Nat. Commun. 9, 4383 (2018).
pubmed: 30348985
pmcid: 6197289
doi: 10.1038/s41467-018-06318-7
Dobie, R. et al. Single-cell transcriptomics uncovers zonation of function in the mesenchyme during liver fibrosis. Cell Rep. 29, 1832–1847.e8 (2019).
pubmed: 31722201
pmcid: 6856722
doi: 10.1016/j.celrep.2019.10.024
Verfaillie, T. et al. PERK is required at the ER–mitochondrial contact sites to convey apoptosis after ROS-based ER stress. Cell Death Differ. 19, 1880–1891 (2012).
pubmed: 22705852
pmcid: 3469056
doi: 10.1038/cdd.2012.74
Liu, J. et al. Endoplasmic reticulum stress modulates liver inflammatory immune response in the pathogenesis of liver ischemia and reperfusion injury. Transplantation 94, 211–217 (2012).
pubmed: 22790388
pmcid: 3414672
doi: 10.1097/TP.0b013e318259d38e
Ren, F. et al. Endoplasmic reticulum stress-activated glycogen synthase kinase 3β aggravates liver inflammation and hepatotoxicity in mice with acute liver failure. Inflammation 38, 1151–1165 (2015).
pubmed: 25630719
doi: 10.1007/s10753-014-0080-2
Wei, C. et al. Tumor microenvironment regulation by the endoplasmic reticulum stress transmission mediator Golgi protein 73 in mice. Hepatology 70, 851–870 (2019).
pubmed: 30723919
doi: 10.1002/hep.30549
Enzan, H. et al. α-Smooth muscle actin-positive perisinusoidal stromal cells in human hepatocellular carcinoma. Hepatology 19, 895–903 (1994).
pubmed: 8138263
Seitz, H. K. & Stickel, F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol. Chem. 387, 349–360 (2006).
pubmed: 16606331
doi: 10.1515/BC.2006.047
Heindryckx, F., Colle, I. & Van Vlierberghe, H. Experimental mouse models for hepatocellular carcinoma research. Int. J. Exp. Pathol. 90, 367–386 (2009).
pubmed: 19659896
pmcid: 2741148
doi: 10.1111/j.1365-2613.2009.00656.x
Carloni, V., Luong, T. V. & Rombouts, K. Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever. Liver Int. 34, 834–843 (2014).
pubmed: 24397349
doi: 10.1111/liv.12465
Baglieri, J., Brenner, D. A. & Kisseleva, T. The role of fibrosis and liver-associated fibroblasts in the pathogenesis of hepatocellular carcinoma. Int. J. Mol. Sci. 20, 1723 (2019).
pmcid: 6479943
doi: 10.3390/ijms20071723
Rosenberg, W. M. et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127, 1704–1713 (2004).
pubmed: 15578508
doi: 10.1053/j.gastro.2004.08.052
Wu, Y., Qiao, X., Qiao, S. & Yu, L. Targeting integrins in hepatocellular carcinoma. Expert. Opin. Ther. Targets 15, 421–437 (2011).
pubmed: 21332366
doi: 10.1517/14728222.2011.555402
Dhar, D., Baglieri, J., Kisseleva, T. & Brenner, D. A. Mechanisms of liver fibrosis and its role in liver cancer. Exp. Biol. Med. 245, 96–108 (2020).
doi: 10.1177/1535370219898141